POSACONAZOLE TIH posaconazole 40 mg/mL oral suspension bottle

Kraj: Australia

Język: angielski

Źródło: Department of Health (Therapeutic Goods Administration)

Składnik aktywny:

posaconazole, Quantity: 40 mg/mL

Dostępny od:

Arrotex Pharmaceuticals Pty Ltd

Forma farmaceutyczna:

Oral Liquid, suspension

Skład:

Excipient Ingredients: PEG-40 hydrogenated castor oil; sodium benzoate; citric acid monohydrate; glycerol; purified water; liquid glucose; xanthan gum; sodium citrate dihydrate; titanium dioxide; PEG-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid; Flavour

Droga podania:

Oral

Sztuk w opakowaniu:

1 x 105 mL bottle

Typ recepty:

(S4) Prescription Only Medicine

Wskazania:

Posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ? Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,Posaconazole is also indicated for the: ? Treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. ? Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.

Podsumowanie produktu:

Visual Identification: Posaconazole 40 mg/mL Suspension is a white to off-white free flowing suspension.; Container Type: Bottle; Container Material: Glass Type III Coloured; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Status autoryzacji:

Registered

Data autoryzacji:

2023-01-18